KD Logo

A company insider recently sold 2,280 shares of Vertex Pharmaceuticals, Inc. [VRTX]. Should You also Consider to Sale?

ZOM Stock

Vertex Pharmaceuticals, Inc.’s recent filing unveils that its EVP and CMO Bozic Carmen unloaded Company’s shares for reported $1.08 million on Jun 26 ’24. In the deal valued at $471.72 per share,2,280 shares were sold. As a result of this transaction, Bozic Carmen now holds 30,099 shares worth roughly $14.5 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Then, Atkinson Edward Morrow III sold 7,288 shares, generating $3,483,664 in total proceeds. Upon selling the shares at $478.00, the EVP, Chief Technical Ops. Off. now owns 15,972 shares.

Before that, Bozic Carmen sold 2,280 shares. Vertex Pharmaceuticals, Inc. shares valued at $1,089,840 were divested by the EVP and CMO at a price of $478.00 per share. As a result of the transaction, Bozic Carmen now holds 32,379 shares, worth roughly $15.6 million.

Redburn Atlantic initiated its Vertex Pharmaceuticals, Inc. [VRTX] rating to a Buy in a research note published on June 27, 2024; the price target was $545. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who increased its forecast for the stock in mid April from “an In-line” to “an Outperform”. Wolfe Research began covering VRTX with “an Outperform” recommendation on February 15, 2024. Evercore ISI revised its rating on February 06, 2024. It rated VRTX as “an In-line” which previously was an “an Outperform”.

Price Performance Review of VRTX

On Monday, Vertex Pharmaceuticals, Inc. [NASDAQ:VRTX] saw its stock jump 1.54% to $481.89. Over the last five days, the stock has gained 2.81%. Vertex Pharmaceuticals, Inc. shares have risen nearly 18.43% since the year began. Nevertheless, the stocks have risen 39.37% over the past one year. While a 52-week high of $486.42 was reached on 06/07/24, a 52-week low of $335.82 was recorded on 04/18/24. SMA at 50 days reached $449.72, while 200 days put it at $407.93. A total of 0.77 million shares were traded, compared to the trading of 0.71 million shares in the previous session.

Levels Of Support And Resistance For VRTX Stock

The 24-hour chart illustrates a support level at 474.81, which if violated will result in even more drops to 467.72. On the upside, there is a resistance level at 485.99. A further resistance level may holdings at 490.08. The Relative Strength Index (RSI) on the 14-day chart is 63.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.95, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 9.82%. Stochastics%K at 59.68% indicates the stock is a holding.

Most Popular